Gene-based diagnostic and treatment methods for tinnitus

International Tinnitus Journal

Volumn 9, Issue 1, 2003, Pages 3-10

  Martin, Donna M ^a   Raphael, Yehoash ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adenovirus gene therapy; Growth factors; Hair cell; Hereditary inner ear disease; Spiral ganglion; Tinnitus

Indexed keywords

ADENOVIRUS VECTOR; ANTIOXIDANT; APOPTOSIS INHIBITOR; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYTOKINE; CYTOKINE INHIBITOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL-LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; NERVE GROWTH FACTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUDITORY SYSTEM; COCHLEAR NERVE; CONFERENCE PAPER; CONTROLLED STUDY; DENERVATION; EAR INJURY; EAR PROTECTION; ELECTROSTIMULATION THERAPY; ENVIRONMENTAL FACTOR; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC ANALYSIS; GENETICS; HAIR CELL; HEREDITY; HUMAN; HUMAN ADENOVIRUS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNER EAR DISEASE; METABOLISM; METHODOLOGY; NEUROEPITHELIUM; NONHUMAN; OTOTOXICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGENERATION; SIDE EFFECT; SPIRAL GANGLION; TINNITUS; VESTIBULAR SYSTEM; VESTIBULOCOCHLEAR NERVE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRUSES, HUMAN; BRAIN-DERIVED NEUROTROPHIC FACTOR; COCHLEAR NERVE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HAIR CELLS; HUMANS; NERVE GROWTH FACTORS; REGENERATION; SPIRAL GANGLION; TINNITUS;

EID: 0038166263     PISSN: 09465448     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (81)

1. Lockwood AH, Salvi RJ, Burkard RF. Tinnitus. N Engl J Med 347(12):904-910, 2002.
2. Bespalova IN, Van Camp G, Bom SJ, et al. Mutations in the Wolfram syndrome 1 gene (WFS1) are a common cause of low frequency sensorineural hearing loss. Hum Mol Genet 10(22):2501-2508, 2001.
3. Komatsu K, Nakamura N, Ghadami M, et al. Confirmation of genetic homogeneity of nonsyndromic low-frequency sensorineural hearing loss by linkage analysis and a DFNA6/14 mutation in a Japanese family. J Hum Genet 47(8):395-399, 2002.
4. Ohata T, Koizumi A, Kayo T, et al. Evidence of an increased risk of hearing loss in heterozygous carriers in a Wolfram syndrome family. Hum Genet 103(4):470-474, 1998.
5. Verstreken M, Declau F, Wuyts FL, et al. Hereditary otovestibular dysfunction and Ménière's disease in a large Belgian family is caused by a missense mutation in the COCH gene. Otol Neurotol 22(6):874-881, 2001.
6. Robertson NG, Lu L, Heller S, et al. Mutations in a novel cochlear gene cause DFNA9, a human nonsyndromic deafness with vestibular dysfunction. Nat Genet 20(3): 299-303, 1998.
7. DeCicco MJ, Hoffer ME, Kopke RD, et al. Round-window microcatheter-administered microdose gentamicin: Results from treatment of tinnitus associated with Ménière's disease. Int Tinnitus J 4(2):141-143, 1998.
8. Seidman MD, Keate B, Howard ML. Re: myths in neurotology, revisited: Smoke and mirrors in tinnitus therapy. Otol Neurotol 23(6):1013-1016, 2002.
9. Seidman MD, Jacobson GP. Update on tinnitus. Otolaryngol Clin North Am 29(3):455-465, 1996.
10. Shulman A. Neuroprotective drug therapy: A medical and pharmacological treatment for tinnitus control. Int Tinnitus J 3(2):77-93, 1997.
11. Nabel EG, Simari R, Yang Z, et al. In vivo gene transfer: A biological tool [review]. Ann N Y Acad Sci 811:289-292, 1997.
12. Anderson WF. Human gene therapy. Nature 392(suppl 6679):25-30, 1998.
13. Costantini LC, Bakowska JC, Breakefield XO, Isacson O. Gene therapy in the CNS [review]. Gene Ther 7(2):93-109, 2000.
14. Amalfitano A, Parks RJ. Separating fact from fiction: Assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther 2(2):111-133, 2002.
15. Staecker H, Gabaizadeh R, Federoff H, Van de Water TR. Brain-derived neurotrophic factor gene therapy prevents spiral ganglion degeneration after hair cell loss. Otolaryngol Head Neck Surg 119(1):7-13, 1998.
16. Yagi M, Magal E, Sheng Z, et al. Hair cell protection from aminoglycoside ototoxicity by adenovirus-mediated overexpression of glial cell line-derived neurotrophic factor. Hum Gene Ther 10(5):813-823, 1999.
17. Yagi M, Kanzaki S, Kawamoto K, et al. Spiral ganglion neurons are protected from degeneration by GDNF gene therapy. J Assoc Res Otolaryngol 1(4):315-325, 2000.
18. Suzuki M, Yagi M, Brown JN, et al. Effect of transgenic GDNF expression on gentamicin-induced cochlear and vestibular toxicity. Gene Ther 7(12):1046-1054, 2000.
19. Bowers WJ, Chen X, Guo H, et al. Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. Mol Ther 6(1):12-18, 2002.
20. Davies AM. Developmental changes in the neurotrophic factor survival requirements of peripheral nervous system neurons [review]. Prog Brain Res 117:47-56, 1998.
21. Shen L, Figurov A, Lu B. Recent progress in studies of neurotrophic factors and their clinical implications [review]. J Mol Med 75(9):637-644, 1997.
22. Shieh PB, Ghosh A. Neurotrophins: New roles for a seasoned cast [review]. Curr Biol 7(10):R627-R630, 1997.
23. Russell JW, Windebank AJ, Schenone A, Feldman EL. Insulin-like growth factor-1 prevents apoptosis in neurons after nerve growth factor withdrawal. J Neurobiol 36(4): 455-467, 1998.
24. Finkbeiner S, Greenberg ME. Ca2+ channel-regulated neuronal gene expression [review]. J Neurobiol 37(1): 171-189, 1998.
25. Bonni A, Greenberg ME. Neurotrophin regulation of gene expression [review]. Can J Neurol Sci 24(4):272-283, 1997.
26. Bianchi LM, Dolnick R, Medd A, Cohan CS. Developmental changes in growth factors released by the embryonic inner ear. Exp Neurol 150(1):98-106, 1998.
27. Fritzsch B, Pirvola U, Ylikoski J. Making and breaking the innervation of the ear: neurotrophic support during ear development and its clinical implications [review]. Cell Tissue Res 295(3):369-382, 1999.
28. Gao WQ. Role of neurotrophins and lectins in prevention of ototoxicity. Ann N Y Acad Sci 884:312-327, 1999.
29. Gao WQ. Therapeutic potential of neurotrophins for treatment of hearing loss [review]. Mol Neurobiol 17(1-3):17-31, 1998.
30. Malgrange B, Rigo JM, Van de Water TR, et al. Growth factor therapy to the damaged inner ear: Clinical prospects [review]. Int J Pediatr Otorhinolaryngol 49(suppl 1):S19-25, 1999.
31. Feghali JG, Lefebvre PP, Staecker H, et al. Mammalian auditory hair cell regeneration/repair and protection: A review and future directions [review]. Ear Nose Throat J 77(4):275-282, 1998.
32. Chen X, Frisina RD, Bowers WJ, et al. HSV amplicon-mediated neurotrophin-3 expression protects murine spiral ganglion neurons from cisplatin-induced damage. Mol Ther 3(6):958-963, 2001.
33. Lin LF, Doherty DH, Lile JD, et al. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260(5111):1130-1132, 1993.
34. Strelau J, Unsicker K. GDNF family members and their receptors: Expression and functions in two oligodendroglial cell lines representing distinct stages of oligodendroglial development. Glia 26(4):291-301, 1999.
35. Ho TW, Bristol LA, Coccia C, et al. TGF-beta trophic factors differentially modulate motor axon outgrowth and protection from excitotoxicity. Exp Neurol 161(2):664-675, 2000.
36. Baloh RH, Enomoto H, Johnson EM Jr, Milbrandt J. The GDNF family ligands and receptors - implications for neural development [review]. Curr Opin Neurobiol 10(1):103-110, 2000.
37. Walton KM. GDNF: A novel factor with therapeutic potential for neurodegenerative disorders. Mol Neurobiol 19(1):43-59, 1999.
38. Treanor JJ, Goodman L, de Sauvage F, et al. Characterization of a multicomponent receptor for GDNF. Nature 382(6586):80-83, 1996.
39. Jing S, Wen D, Yu Y, et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85(7):1113-1124, 1996.
40. Jing S, Yu Y, Fang M, et al. GFR alpha-2 and GFR alpha-3 are two new receptors for ligands of the GDNF family. J Biol Chem 272(52):33111-33117, 1997.
41. Durbec P, Marcos-Gutierrez CV, Kilkenny C, et al. GDNF signaling through the Ret receptor tyrosine kinase. Nature 381(6585):789-793, 1996.
42. Stover T, Gong TL, Cho Y, et al. Expression of the GDNF family members and their receptors in the mature rat cochlea. Brain Res Mol Brain Res 76(1):25-35, 2000.
43. Kawamoto K, Kanzaki S, Yagi M, et al. Gene-based therapy for inner ear disease. Presented at the Sixth International Symposium on Noise-Induced Hearing Loss, Cambridge, UK, 2000.
44. Lindeman HH. Regional differences in sensitivity of the vestibular sensory epithelia to ototoxic antibiotics. Acta Otolaryngol 67:177-189, 1969.
45. Hawkins JE Jr, Preston RE. Vestibular Ototoxicity. In RF Naunton (ed.), The Vestibular System. New York: Academic Press, 1975:321-349.
46. Meiteles LZ, Raphael Y. Scar formation in the vestibular sensory epithelium after aminoglycoside toxicity. Hear Res 79:26-38, 1994.
47. Forge A, Li L, Nevill G. Hair cell recovery in the vestibular sensory epithelia of mature guinea pigs. J Comp Neurol 397:69-88, 1998.
48. Lopez I, Honrubia V, Lee SC, et al. Hair cell recovery in the chinchilla crista ampullaris after gentamicin treatment: A quantitative approach. Otolaryngol Head Neck Surg 119:255-262, 1998.
49. Webster DB, Webster M. Cochlear nerve projections following organ of Corti destruction. Otolaryngology 86(2):342-353, 1978.
50. Bichler E, Spoendlin H, Rauchegger H. Degeneration of cochlear neurons after amikacin intoxication in the rat. Arch Otorhinolaryngol 237(3):201-208, 1983.
51. Leake PA, Hradek GT. Cochlear pathology of long term neomycin induced deafness in cats. Hear Res 33(1):11-33, 1988.
52. Nadol JB Jr. Patterns of neural degeneration in the human cochlea and auditory nerve: Implications for cochlear implantation. Otolaryngol Head Neck Surg 117(3):220-228, 1997.
53. Sutton D, Miller JM. Cochlear implant effects on the spiral ganglion. Ann Otol Rhinol Laryngol 92(1):53-58, 1983.
54. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist [review]. Int Rev Immunol 16(5-6):457-499, 1998.
55. Lennard AC. Interleukin-1 receptor antagonist. Crit Rev Immunol 15(1):77-105, 1995.
56. Patterson JC, Childs GV. Nerve growth factor in the anterior pituitary: Regulation of secretion. Endocrinology 135(4):1697-1704, 1994.
57. Friedman WJ, Thakur S, Seidman L, Rabson AB. Regulation of nerve growth factor mRNA by interleukin-1 in rat hippocampal astrocytes is mediated by NF kappa B. J Biol Chem 271(49):31115-31120, 1996.
58. Komeda M, Roessler BJ, Raphael Y. The influence of interleukin-1 receptor antagonist transgene on spiral ganglion neurons. Hear Res 131(1-2):1-10, 1999.
59. Hartshorn DO, Miller JM, Altschuler RA. Protective effect of electrical stimulation in the deafened guinea pig cochlea. Otolaryngol Head Neck Surg 104(3):311-319, 1991.
60. Leake PA, Hradek GT, Snyder RL. Chronic electrical stimulation by a cochlear implant promotes survival of spiral ganglion neurons after neonatal deafness. J Comp Neurol 412(4):543-562, 1999.
61. Lousteau RJ. Increased spiral ganglion cell survival in electrically stimulated, deafened guinea pig cochleae. Laryngoscope 97(7):836-842, 1987.
62. Mitchell A, Miller JM, Finger PA, et al. Effects of chronic high-rate electrical stimulation on the cochlea and eighth nerve in the deafened guinea pig. Hear Res 105(1-2):30-43, 1997.
63. Nadol JB Jr, Ketten DR, Burgess BJ. Otopathology in a case of multichannel cochlear implantation. Laryngoscope 104(3):299-303, 1994.
64. Shepherd RK, Clark GM, Black RC, Patrick JF. The histopathological effects of chronic electrical stimulation of the cat cochlea. J Laryngol Otol 97(4):333-341, 1983.
65. Sutton D. Cochlear implant effects on the spiral ganglion. Ann Otol Rhinol Laryngol 92(3):316, 1983.
66. Kanzaki S, Stover T, Kawamoto K, et al. Glial cell line-derived neurotrophic factor and chronic electrical stimulation prevent VIII cranial nerve degeneration following denervation. J Comp Neurol 454(3):350-360, 2002.
67. Lalwani AK, Han JJ, Walsh BJ, et al. Green fluorescent protein as a reporter for gene transfer studies in the cochlea. Hear Res 114(1-2):139-147, 1997.
68. Stover T, Yagi M, Raphael Y. Transduction of the contralateral ear after adenovirus-mediated cochlear gene transfer. Gene Ther 7(5):377-383, 2000.
69. Ishimoto SI, Kawamoto K, Stover T, et al. A glucocorticoid reduces adverse effects of adenovirus vectors in the cochlea. Audiol Neurootol 8:70-79, 2003.
70. Balicki D, Beutler E. Gene therapy of human disease. Medicine (Baltimore) 81(1):69-86, 2002.
71. Vadolas J, Williamson R, Ioannou PA. Gene therapy for inherited lung disorders: An insight into pulmonary defence. Pulm Pharmacol Ther 15(1):61-72, 2002.
72. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275(5301):838-841, 1997.
73. Hsich G, Sena-Esteves M, Breakefield XO. Critical issues in gene therapy for neurologic disease. Hum Gene Ther 13(5):579-604, 2002.
74. Segovia J. Gene therapy for Parkinson's disease: Current status and future potential. Am J Pharmacogenom 2(2):135-146, 2002.
75. McBride JL, Kordower JH. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog Brain Res 138:421-432, 2002.
76. Walsh CE. Gene therapy for the hemophilias. Curr Opin Pediatr 14(1):12-16, 2002.
77. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346(16):1185-1193, 2002.
78. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28(1):92-95, 2001.
79. Duckers HJ, Nabel EG. Prospects for genetic therapy of cardiovascular disease. Med Clin North Am 84(1):199-213, 2000.
80. Isner JM. Myocardial gene therapy. Nature 415(6868): 234-239, 2002.
81. Probst FJ, Fridell RA, Raphael Y, et al. Correction of deafness in shaker-2 mice by an unconventional myosin in a BAC transgene. Science 280(5368):1444-1447, 1998.